Medicine
Cefpodoxime 50 mg/5 mL oral suspension
Cefpodoxime 50 mg/5 mL oral suspension is a generic prescription medicine for oral use, made by 3 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store unsuspended granules at 20° to 25°C (68° to 77°F), excursions permitted…
Key facts
- Active ingredient (INN)
- Cefpodoxime
- Brand
- Sold under the generic name
- Strength
- 50 mg/5 mL
- Dosage form
- Oral suspension
- Route
- Oral
- Packs
- 1 bottle and 4 more
- Manufacturers
- Aurobindo PharmaIndiaNorthStar RxRising Pharma Holdings
- Origin register
- US FDA, United States
- Storage
- Store unsuspended granules at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F). After mixing, suspension should be stored in a refrigerator, 2° to 8°C (36° to 46°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J01DD13 Cefpodoxime
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 June 2007
- Identifiers
- RxCUI 309077, 309079DailyMed set ID 63777889-d306-4fc3-88da-b24859040ef4, edf589b2-f796-4522-a5e6-2bd0a833922f, 5310de78-22c3-4bee-9956-854e767b6befNDC 65862-140, 64980-402, 16714-402Application ANDA065409
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 100 mL in 1 bottle | 65862-140-01 | Aurobindo PharmaIndia | 8 June 2007 |
| 1 bottle in 1 carton / 50 mL in 1 bottle | 65862-140-50 | Aurobindo PharmaIndia | 8 June 2007 |
| 1 bottle in 1 carton / 75 mL in 1 bottle | 65862-140-75 | Aurobindo PharmaIndia | 8 June 2007 |
| 1 bottle in 1 carton / 100 mL in 1 bottle | 64980-402-10 | Rising Pharma Holdings | 8 June 2007 |
| 1 bottle in 1 carton / 50 mL in 1 bottle | 64980-402-50 | Rising Pharma Holdings | 8 June 2007 |
| 1 bottle in 1 carton / 50 mL in 1 bottle | 16714-402-01 | NorthStar Rx | 8 June 2007 |
| 1 bottle in 1 carton / 100 mL in 1 bottle | 16714-402-02 | NorthStar Rx | 8 June 2007 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 7 August 1992 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Cefpodoxime
Clinical summary
Cefpodoxime is a cephalosporin antibacterial indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. It is available as tablets and oral suspension. MedsAcross supplies Cefpodoxime for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CefpodoximeFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cefpodoxime Proxetil prescribing information (Ascend Laboratories) · U.S. National Library of Medicine, DailyMed
Need Cefpodoxime 50 mg/5 mL oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.